HLA Class II Immunopeptidomics Services | HLA-DR, DQ & DP

Direct Profiling of the HLA Class II Ligandome

HLA class II peptidomics addresses a specific experimental question: which peptides are actually processed and displayed by HLA-II molecules in the biological system being studied? HLA-DR, HLA-DQ, and HLA-DP present peptide antigens to CD4+ T cells, but the displayed repertoire is shaped by HLA genotype, source-protein availability, intracellular processing, peptide loading and editing, and the cellular state of the antigen-presenting system.

Unlike peptide-binding prediction or screening of predefined candidates, immunopeptidomics isolates peptide-HLA complexes from the sample itself and identifies the eluted ligands by LC-MS/MS. This provides direct evidence of presentation and helps researchers move from a large theoretical antigen space to experimentally observed HLA-II peptides. For broader class I and class II projects, see our HLA Peptidomics platform.

Why HLA-II Requires a Dedicated Peptidomics Strategy

HLA-II ligands differ from conventional tryptic proteomics peptides and from the shorter, more tightly length-constrained HLA-I ligandome. Many HLA-II peptides occur as nested sets: overlapping N- and C-terminal variants that share a central binding region. HLA-II molecules also have an open-ended peptide-binding groove, allowing variable peptide extensions around the binding core. In multiallelic samples, several HLA-DR, HLA-DQ, and HLA-DP heterodimers can contribute to the same measured ligandome.

These features make class II-specific experimental design and interpretation essential. Peptide length, nested-set structure, motif consistency, source-protein context, HLA typing, and binding predictions are evaluated together rather than treating every identified sequence as an independent epitope or assigning an allele solely from sequence prediction.

Representative source-protein origin analysis of HLA-II ligands, illustrating how identified peptides can be contextualized by their biological source categories.

HLA-II Targets and Analysis Modules

The enrichment and bioinformatics strategy should reflect the HLA-II loci and biological question of the study. Creative Proteomics can scope projects around HLA-DR, HLA-DQ, HLA-DP, or mixed HLA-II presentation, with interpretation adapted to monoallelic or multiallelic contexts.

HLA-DR Ligand Profiling

Characterize naturally presented HLA-DR peptides, map nested ligand regions, and evaluate binding motifs and source proteins in HLA-DR-focused or mixed class II samples.

HLA-DQ Ligand Profiling

Investigate HLA-DQ-associated peptides with attention to alpha/beta-chain pairing, allele context, motif deconvolution, and the interpretation challenges of multiallelic HLA-II samples.

HLA-DP Ligand Profiling

Profile HLA-DP-presented peptides for antigen-presentation, immune-recognition, and HLA-DP repertoire studies, with locus-aware annotation when the HLA background is available.

Mixed HLA-II Immunopeptidome Profiling

Survey the combined class II ligandome in HLA-diverse material and use HLA typing, sequence motifs, deconvolution, and binding predictions to support candidate allele attribution.

Comparative HLA-II Presentation

Compare peptide presentation between experimental states when study design, sample quality, replication, and acquisition strategy support robust groupwise interpretation.

Extended Peptide Annotation

Project-specific searches can be designed to investigate selected modifications, sequence variants, or non-canonical peptide sources when suitable reference data and validation criteria are available.

Representative HLA-DR HLA-DQ and HLA-DP repertoire comparison
Representative comparison of HLA-DR, HLA-DQ, and HLA-DP peptide repertoires, highlighting shared and locus-associated presentation patterns.

Applications of HLA Class II Peptidomics

Because HLA-II peptidomics measures the products of antigen processing and presentation, it is most useful when the research question depends on what CD4+ T cells may encounter in a defined biological context rather than on peptide sequence or binding affinity alone.

CD4+ T Cell Epitope Discovery

Identify naturally presented candidate epitopes and prioritize peptide regions for downstream immune-recognition studies.

Vaccine and Infectious Disease Research

Map HLA-II-presented regions from pathogen or vaccine-related antigens to support experimental epitope selection and antigen-presentation research.

Autoimmune Antigen Research

Characterize self-derived HLA-II ligands and altered presentation patterns relevant to tolerance, inflammation, or autoimmune mechanism studies.

Tumor Antigen Presentation Research

Explore tumor-associated, variant-derived, or treatment-responsive HLA-II ligands as an experimental layer for CD4+ T-cell antigen research.

For projects centered specifically on tumor antigen discovery and prioritization across broader immunopeptidomic and proteogenomic evidence, our Neoantigen Discovery workflow provides the more appropriate project framework.

HLA Class II Immunopeptidomics Workflow

Sample & Study Design

Define sample context, HLA-II targets, comparison groups, and available HLA typing

HLA-II Immunoaffinity Enrichment

Enrich HLA-DR, HLA-DQ, HLA-DP, or mixed HLA-II complexes according to project scope

Peptide Elution, Cleanup & LC-MS/MS

Release endogenous HLA-II ligands, reduce matrix interference, and acquire tandem MS data

Peptide Identification & HLA-II Assignment

Identify non-tryptic ligands, map source proteins, group nested peptides, and integrate HLA context

Motif, Binding-Core & Biological Interpretation

Summarize peptide length, motifs, candidate binding regions, comparative presentation, and prioritized outputs

Sample and Study Design

The workflow begins by defining the biological material, HLA-II loci of interest, study groups, HLA typing information, and downstream evidence required. This determines whether the project should focus on HLA-DR, HLA-DQ, HLA-DP, or a broader class II repertoire.

HLA-II Immunoaffinity Enrichment

HLA-II peptide complexes are isolated from appropriately prepared research samples. Capture strategy is matched to the intended HLA-II coverage because antibody recognition and HLA expression influence the ligand repertoire recovered.

Peptide Elution, Cleanup and LC-MS/MS

HLA-bound peptides are released from enriched complexes, cleaned to reduce matrix interference, and analyzed by high-resolution LC-MS/MS without assuming tryptic cleavage.

Peptide Identification and HLA-II Assignment

Peptides are identified with stringent quality control, mapped to source proteins, and consolidated into overlapping or nested regions. HLA typing, motif deconvolution, and binding predictions can be integrated to support allele-aware interpretation.

Motif, Binding-Core and Biological Interpretation

Results are summarized through peptide-length patterns, nested regions, motif and candidate binding-core analysis, source-protein context, comparative presentation, and project-specific candidate prioritization.

From Peptide Identifications to HLA-II Binding Regions

A list of peptide-spectrum matches is only the starting point for HLA-II analysis. Class II datasets often contain multiple overlapping peptides from the same source-protein region. These nested ligands may share a common binding core but differ in their N- and C-terminal extensions. Treating each sequence as a separate biological epitope can therefore inflate apparent diversity and obscure the underlying presented region.

Our HLA-II interpretation framework emphasizes the relationship among peptide sequence, source-protein position, nested-set structure, length distribution, motif consistency, and HLA allele context. In multiallelic samples, computational assignment is reported as supporting evidence rather than as direct proof of a peptide's restricting allele unless the experimental design provides allele-specific evidence.

HLA Class II vs. HLA Class I Peptidomics

Feature	HLA Class II Peptidomics	HLA Class I Peptidomics
Primary HLA loci	HLA-DR, HLA-DQ, HLA-DP	HLA-A, HLA-B, HLA-C
Principal T-cell context	CD4+ T-cell antigen recognition	CD8+ T-cell antigen recognition
Typical ligand architecture	Longer, heterogeneous peptides with variable flanking residues and frequent nested sets	Shorter peptides with more constrained length distributions
Binding groove	Open-ended groove; binding core is contained within a longer peptide	Closed-ended groove constrains peptide termini more strongly
Major processing context	Endosomal/lysosomal processing is central; endogenous proteins can also contribute through autophagy and related pathways	Cytosolic protein degradation and ER loading are major contributors, with additional alternative pathways
Key analysis challenge	Nested ligands, multiple alpha/beta-chain combinations, peptide editing, and multiallelic deconvolution	Allele assignment, low abundance, source-protein interpretation, and non-canonical ligand detection

Choosing the Right HLA-II Research Workflow

HLA-II peptidomics is not interchangeable with every MHC-related assay. The most informative workflow depends on whether the project needs evidence of natural presentation, binding of predefined peptides, processing of a defined protein, or downstream receptor recognition.

Research Question	Best-Fit Approach	What It Establishes
Which peptides are naturally presented by HLA-II in my biological sample?	HLA Class II Peptidomics	Direct MS evidence of naturally presented HLA-II ligands
Does a predefined peptide bind a selected MHC/HLA molecule?	MHC Binding & Epitope Screening	Candidate peptide binding or screening evidence; does not by itself prove natural processing and presentation
Which peptides from a defined protein are processed and presented by antigen-presenting cells?	MAPPs Immunogenicity Assessment	Processing and HLA-II presentation of peptides derived from a specified test protein in an APC-based workflow
Does a prioritized peptide-HLA complex support receptor-level recognition?	TCR-pMHC Validation	Downstream evidence for peptide-HLA/TCR recognition in the selected validation system

Sample Requirements and Study Design

HLA-II immunopeptidome depth depends on more than total sample mass. The abundance and composition of HLA-II complexes, cell type, inflammatory or activation state, HLA genotype, sample handling, capture specificity, and biological heterogeneity can all affect the recovered ligand repertoire. For this reason, sample requirements should be defined after reviewing the biological material and study objective rather than applying a universal minimum-input value.

Design Element	Recommended Information	Why It Matters
Sample type	Cell line, primary immune-cell preparation, antigen-presenting cell model, or tissue-based research material	HLA-II abundance and antigen-processing biology vary substantially across sample types
HLA background	HLA-DR/DQ/DP typing when available, especially for multiallelic donor-derived material	Supports motif interpretation and candidate peptide-to-allele assignment
Target HLA-II coverage	DR only, DQ only, DP only, locus combination, or broad HLA-II survey	Guides immunoaffinity capture and prevents overinterpretation of loci not efficiently represented in the enrichment
Study groups	Controls, perturbations, biological replicates, and batch structure	Determines whether comparative presentation analysis is statistically interpretable
Candidate validation plan	Sequence confirmation, MHC binding, pMHC/TCR testing, or functional T-cell assays	Helps define the evidence threshold needed during discovery and prioritization

HLA-II-Specific Data Analysis and Interpretation

Direct Presentation Evidence

Prioritize peptides supported by tandem MS evidence from enriched HLA-II complexes rather than relying solely on predicted binders.

Nested-Peptide Consolidation

Group overlapping ligand sequences into presented regions to reduce redundancy and improve interpretation of the underlying HLA-II binding core.

Motif and Allele Context

Combine sequence motifs, HLA typing, deconvolution, and binding predictions to support allele-aware annotation while retaining uncertainty in multiallelic datasets.

Source-Protein Mapping

Trace HLA-II ligands to source proteins and peptide regions to support antigen-processing, pathway, and candidate-antigen interpretation.

Project-Specific Search Space

Adapt search databases and modification settings to the research question when variant, modified, pathogen-derived, or non-canonical peptides are scientifically justified.

Transparent Evidence Ranking

Separate direct MS observations from inferred HLA restriction, binding prediction, biological annotation, and downstream immunogenicity hypotheses.

Representative Results

The visualizations below illustrate common result formats for HLA-II immunopeptidomics, complementing the source-origin and HLA-DR/DQ/DP repertoire views shown earlier on this page. Actual plots, comparisons, and annotations are generated from project-specific data and study design.

HLA-II Peptide Length Distribution

Representative HLA class II peptide length distribution

HLA-II Binding Motif and Sequence Logo

Representative HLA class II binding motif sequence logo

Nested Peptide and Binding-Core Alignment

Representative nested HLA class II peptide alignment and binding core

Differential HLA-II Peptide Presentation

Representative differential HLA class II peptide presentation volcano plot

Representative outputs are illustrative and are not presented as data from a specific customer project. Final figures depend on sample type, HLA context, study design, and data quality.

Typical Deliverables

Deliverables are matched to the project design and may include the following analytical outputs:

HLA-II Peptide Identification Table
Identified peptide sequences with peptide-level MS evidence, precursor information, and search-confidence fields appropriate to the selected workflow.
Source-Protein and Position Mapping
Mapping of HLA-II ligands to source proteins and protein coordinates, including overlapping or nested peptide regions.
Peptide Length and Nested-Set Analysis
Length distributions and consolidation of overlapping HLA-II ligands into shared presented regions.
Motif and HLA Annotation
Sequence motif visualization and candidate HLA-DR/DQ/DP assignments when supported by HLA context and the selected analysis strategy.
Comparative Presentation Results
For appropriately designed multi-group studies, quantitative or presence/absence summaries of condition-associated HLA-II presentation patterns.
Functional and Candidate-Prioritization Annotations
Optional source-protein, pathway, antigen-category, binding-prediction, or custom annotations selected during project scoping.
Analytical Report and Data Package
A structured report with methods, quality-control summaries, key visualizations, interpretation notes, and project-specific data files.

References

Ramarathinam SH, Ho BK, Dudek NL, Purcell AW. HLA class II immunopeptidomics reveals that co-inherited HLA-allotypes within an extended haplotype can improve proteome coverage for immunosurveillance. Proteomics. 2021;21:e2000160. https://doi.org/10.1002/pmic.202000160
Stražar M, et al. HLA-II immunopeptidome profiling and deep learning reveal features of antigenicity to inform antigen discovery. Immunity. 2023;56:1681-1698.e13. https://doi.org/10.1016/j.immuni.2023.05.009
Santambrogio L. Molecular Determinants Regulating the Plasticity of the MHC Class II Immunopeptidome. Front Immunol. 2022;13:878271. https://doi.org/10.3389/fimmu.2022.878271
Álvaro-Benito M, Morrison E, Abualrous ET, Kuropka B, Freund C. Quantification of HLA-DM-Dependent Major Histocompatibility Complex of Class II Immunopeptidomes by the Peptide Landscape Antigenic Epitope Alignment Utility. Front Immunol. 2018;9:872. https://doi.org/10.3389/fimmu.2018.00872
Jurewicz MM, Stern LJ. Class II MHC antigen processing in immune tolerance and inflammation. Immunogenetics. 2019;71:171-187. https://doi.org/10.1007/s00251-018-1095-x

For research use only. Not for use in diagnostic or therapeutic procedures.

FAQ for HLA Class II Peptidomics

How is HLA class II peptidomics different from HLA class I peptidomics? +

HLA-II peptidomics focuses on peptides presented by HLA-DR, HLA-DQ, and HLA-DP to CD4+ T cells. These ligands are generally longer and more heterogeneous than HLA-I ligands and frequently appear as nested peptide sets around shared binding regions. The enrichment strategy, search parameters, motif interpretation, and allele-deconvolution approach should therefore be tailored specifically to HLA-II.

Can HLA-DR, HLA-DQ, and HLA-DP all be analyzed? +

Projects can be designed around HLA-DR, HLA-DQ, HLA-DP, or broader class II coverage. The optimal enrichment strategy depends on the HLA loci of interest, antibody-capture characteristics, HLA expression in the sample, and available HLA typing. These points should be defined before sample submission.

Do I need HLA typing before HLA-II immunopeptidomics? +

HLA typing is strongly recommended when allele-aware interpretation is important, particularly for multiallelic donor-derived samples. A global HLA-II ligand survey may still be possible without complete typing, but peptide-to-allele attribution will be more limited and should be reported with appropriate uncertainty.

Does an identified HLA-II peptide prove that it is immunogenic? +

No. Immunopeptidomics provides direct evidence that a peptide was detected in the enriched HLA-II ligand pool. Immunogenicity additionally depends on T-cell repertoire, peptide-HLA stability, abundance, receptor recognition, and biological context. Candidate peptides should be validated with an assay matched to the downstream research question.

Does non-detection mean an HLA-II peptide is absent from the sample? +

No. A peptide may remain unobserved because of low HLA-II abundance, limited sample input, enrichment efficiency, peptide stability or ionization, chromatographic behavior, acquisition depth, or stochastic sampling. Non-detection should therefore be interpreted as not observed under the selected analytical conditions rather than as definitive evidence of biological absence.

How are peptides assigned to HLA-DR, HLA-DQ, or HLA-DP alleles? +

Assignment can integrate the enrichment design, HLA typing, peptide motifs, motif deconvolution, and HLA-II binding predictions. In multiallelic samples, these assignments may remain probabilistic. Direct allele restriction is strongest when the experimental system or enrichment strategy provides locus- or allele-specific evidence.

Why do HLA-II datasets contain many overlapping peptide sequences? +

The HLA-II binding groove is open at both ends, and antigen processing can generate ligands with different N- and C-terminal extensions around a shared core. These related sequences form nested sets. Grouping nested peptides helps distinguish a shared presented region from multiple independent epitopes.

Can HLA-II peptidomics identify modified, variant, or non-canonical peptides? +

Potentially, but the search space must be defined carefully. Selected PTMs, sequence variants, pathogen-derived sequences, or non-canonical sources can be incorporated when the biological rationale, reference database, sample design, and validation strategy support the analysis. Expanding the search space without adequate controls can increase false-positive risk.

Can I compare HLA-II peptide presentation between experimental conditions? +

Yes, when samples are collected and processed using a balanced design with suitable biological replication and consistent enrichment and MS acquisition. Comparative interpretation should consider changes in HLA-II abundance as well as changes in the ligand repertoire itself.

What sample types are suitable for HLA-II immunopeptidomics? +

HLA-II-expressing cell lines, antigen-presenting cell preparations, primary immune-cell material, and tissue-based research samples may be suitable. Feasibility depends on HLA-II abundance, sample quality, biological heterogeneity, and project goals, so input requirements should be confirmed for the specific material before submission.

How does HLA-II peptidomics differ from peptide-HLA binding prediction? +

Prediction estimates whether a sequence is likely to bind an HLA-II molecule. HLA-II immunopeptidomics measures peptides recovered from HLA-II complexes in a biological sample, so it captures the combined effects of protein availability, antigen processing, peptide loading, HLA-DM/HLA-DO editing, and presentation. Prediction remains useful for annotation and prioritization but is not a substitute for direct presentation evidence.

What is the best next step after discovering an HLA-II candidate peptide? +

The validation path depends on the claim you need to establish. Options may include synthetic-peptide MS confirmation, peptide-HLA binding assessment, pMHC reagent studies, TCR recognition, or functional CD4+ T-cell assays. Defining the validation endpoint before discovery helps set the appropriate evidence threshold for candidate prioritization.